Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

Description

This study evaluates the efficacy of single strain probiotic administered in a form of a sachet in the treatment of infant colic in infants 3-12 weeks old.

Conditions

Infantile Colic

Study Overview

Study Details

Study overview

This study evaluates the efficacy of single strain probiotic administered in a form of a sachet in the treatment of infant colic in infants 3-12 weeks old.

A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

Condition
Infantile Colic
Intervention / Treatment

-

Contacts and Locations

Chicago

Atlantia Food Clinical Trials, Chicago, Illinois, United States, 60611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Gestational age of minimum 37 weeks.
  • * Birthweight of minimum 2500 g (5.5 lb.).
  • * Age of greater than 3 weeks and less than 12 weeks at enrolment.
  • * Confirmed Infantile colic defined as: parental report of crying and/or fussing ≥3 hours/day for ≥3 days/week, confirmed prior to enrolment with an infant behaviour diary recording \>3 hours of crying in a 24-hour period (eDiary App completed daily during run-in period \& for duration of study).
  • * Participant Informed Consent form signed by parent or legal guardian.
  • * Infant is considered healthy following physical exam.
  • * Parents/Caregivers are willing to comply with the trial procedures, and the mother of the infant can attend all three trial visits
  • * Use of antibiotics by the infant within 2-weeks prior to the screening visit or during the run-in period of the trial.
  • * Use of probiotic supplements from child's birth to enrolment (this includes infant formulas containing probiotics).
  • * Need for hospitalization (defined as readmission to a hospital ward after initial discharge following delivery).
  • * Congenital disorders that, in the opinion of the investigator, would impact the gastrointestinal tract.
  • * Failure to thrive.
  • * Known lactose or gluten intolerance.
  • * Known allergy to cow's milk proteins, fish, or any of the substances of the trial product or placebo.
  • * Known other causes for abdominal pain (e.g., pyloric stenosis).
  • * Participation in any other interventional clinical study.
  • * Immuno-compromised participant or participant with other severe chronic disorder.
  • * Use of probiotic supplements by breastfeeding mother from child's birth to enrolment.
  • * Use of antibiotics by breastfeeding mother within 2-weeks prior to the screening visit or during the run-in period of the trial.
  • * Any Participant/Parent/Caregiver who is an employee of the investigational site or an Atlantia Clinical Trials employee or their close family member or a member of their household.

Ages Eligible for Study

3 Weeks to 12 Weeks

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

The Archer-Daniels-Midland Company,

Study Record Dates

2026-05